Want to join the conversation?
In 2Q16, R&D expense grew by 7.6% or $7.2MM to $102.5MM from $95.3MM in 2Q15. The increase mainly resulted from the expansion of the engineering group due to direct hires and business combinations, as $RHT continues to invest in cloud management and its other emerging technologies. R&D expense was 20.3% of total revenue in 2Q16.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?